628 related articles for article (PubMed ID: 25688158)
1. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
2. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
Buurman R; Sandbothe M; Schlegelberger B; Skawran B
Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
[TBL] [Abstract][Full Text] [Related]
6. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.
Hess L; Moos V; Lauber AA; Reiter W; Schuster M; Hartl N; Lackner D; Boenke T; Koren A; Guzzardo PM; Gundacker B; Riegler A; Vician P; Miccolo C; Leiter S; Chandrasekharan MB; Vcelkova T; Tanzer A; Jun JQ; Bradner J; Brosch G; Hartl M; Bock C; Bürckstümmer T; Kubicek S; Chiocca S; Bhaskara S; Seiser C
PLoS Genet; 2022 Aug; 18(8):e1010376. PubMed ID: 35994477
[TBL] [Abstract][Full Text] [Related]
7. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
8. HDAC1 and HDAC2 regulate anti-inflammatory effects of anesthetic isoflurane in human monocytes.
Guo X; Deng J; Zheng B; Liu H; Zhang Y; Ying Y; Jia J; Ruan X
Immunol Cell Biol; 2020 Apr; 98(4):318-331. PubMed ID: 31950542
[TBL] [Abstract][Full Text] [Related]
9. Modulation of STAT1-Driven Transcriptional Activity by Histone Deacetylases.
Owusu BY; Klampfer L
Methods Mol Biol; 2017; 1510():277-285. PubMed ID: 27761828
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Kikuchi J; Wada T; Shimizu R; Izumi T; Akutsu M; Mitsunaga K; Noborio-Hatano K; Nobuyoshi M; Ozawa K; Kano Y; Furukawa Y
Blood; 2010 Jul; 116(3):406-17. PubMed ID: 20351311
[TBL] [Abstract][Full Text] [Related]
11. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.
Frumm SM; Fan ZP; Ross KN; Duvall JR; Gupta S; VerPlank L; Suh BC; Holson E; Wagner FF; Smith WB; Paranal RM; Bassil CF; Qi J; Roti G; Kung AL; Bradner JE; Tolliday N; Stegmaier K
Chem Biol; 2013 May; 20(5):713-25. PubMed ID: 23706636
[TBL] [Abstract][Full Text] [Related]
12. HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis.
Zimberlin CD; Lancini C; Sno R; Rosekrans SL; McLean CM; Vlaming H; van den Brink GR; Bots M; Medema JP; Dannenberg JH
FASEB J; 2015 May; 29(5):2070-80. PubMed ID: 25648995
[TBL] [Abstract][Full Text] [Related]
13. Selective HDAC inhibition for the disruption of latent HIV-1 infection.
Barton KM; Archin NM; Keedy KS; Espeseth AS; Zhang YL; Gale J; Wagner FF; Holson EB; Margolis DM
PLoS One; 2014; 9(8):e102684. PubMed ID: 25136952
[TBL] [Abstract][Full Text] [Related]
14. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2.
Icardi L; Lievens S; Mori R; Piessevaux J; De Cauwer L; De Bosscher K; Tavernier J
FASEB J; 2012 Jan; 26(1):240-9. PubMed ID: 21957129
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
[TBL] [Abstract][Full Text] [Related]
16. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
17. Effect of Histone Deacetylase Inhibition on the Expression of Multidrug Resistance-associated Protein 2 in a Human Placental Trophoblast Cell Line.
Duan HY; Ma D; Zhou KY; Wang T; Zhang Y; Li YF; Wu JL; Hua YM; Wang C
Chin Med J (Engl); 2017 Jun; 130(11):1352-1360. PubMed ID: 28524836
[TBL] [Abstract][Full Text] [Related]
18. HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation.
Nalawansha DA; Gomes ID; Wambua MK; Pflum MKH
Cell Chem Biol; 2017 Apr; 24(4):481-492.e5. PubMed ID: 28392145
[TBL] [Abstract][Full Text] [Related]
19. Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
Lund RJ; Emani MR; Barbaric I; Kivinen V; Jones M; Baker D; Gokhale P; Nykter M; Lahesmaa R; Andrews PW
Stem Cell Res; 2013 Nov; 11(3):1022-36. PubMed ID: 23941963
[TBL] [Abstract][Full Text] [Related]
20. Podocyte histone deacetylase activity regulates murine and human glomerular diseases.
Inoue K; Gan G; Ciarleglio M; Zhang Y; Tian X; Pedigo CE; Cavanaugh C; Tate J; Wang Y; Cross E; Groener M; Chai N; Wang Z; Justice A; Zhang Z; Parikh CR; Wilson FP; Ishibe S
J Clin Invest; 2019 Mar; 129(3):1295-1313. PubMed ID: 30776024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
